Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06273588 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 50 microgram PF-06273588 intravenous | EXPERIMENTAL | Subjects will receive a single intravenous microdose of PF-06273588 in period one |
| 50 microgram PF-06273588 oral | EXPERIMENTAL | Subjects will receive a single oral microdose of PF-06273588 in period two |
| Name | Type | Description |
|---|---|---|
| PF-06273588 | DRUG | Intravenous, 50 microgram, single dose |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical...
PF-06273588 is an investigational small molecule being studied in healthy volunteers. It is being evaluated to understand how the drug is eliminated from the body after a single low dose. The drug is in Phase 1 clinical development and is not yet approved for any medical use.
PF-06273588 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to investigate the properties of this investigational small molecule drug.
PF-06273588 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its elimination from the body following a single low dose.
PF-06273588 has one completed clinical trial registered as NCT01408355. This Phase 1 study investigated the elimination of PF-06273588 from the body following a single low dose. The trial enrolled 5 healthy male volunteers in the United Kingdom and has been completed.
PF-06273588 is the primary identifier for this investigational drug. No alternative names have been reported for this compound in clinical trial registrations. It is a small molecule being developed by Pfizer for research purposes in healthy volunteers.